Atea reports Q4 net income of $117.1M on Roche revenue recognition; pivots COVID-19 pipeline to combo

Atea Pharmaceuticals, Inc.

2021-FY EPS reported $1.37 revenue$351,367,000

Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.
Phase 3 MORNINGSKY trial closed; COVID-19 program shifts to Phase 2 combination with a protease inhibitor in 2H 2022.
Initiated Phase 2 HCV combination trial of bemnifosbuvir and ruzasvir (in-licensed from Merck) in 2H 2022.
AT-752 Phase 2 dengue program expected to start 1H 2022 with results late 2022; cash $764.4M at Dec 31, 2021.
Roche collaboration terminated effective Feb 10, 2022; Atea regains full worldwide rights to bemnifosbuvir.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.